Analysts surveyed by LSEG are expecting Amazon to report revenue of $187 billion for its latest quarter on Thursday.

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

RADIO AIRPLAY AUDIENCE IMPRESSIONS AS PROVIDED BY LUMINATE AND SALES DATA AS COMPILED BY LUMINATE Tyla Last week Weeks at no. 1 Weeks on chart T.L.Seethal, I.Lewis, C.M.Lindsay-Keay, A.Irosogie ...

President Donald Trump signed an executive order pulling the U.S. out of the W.H.O. Winter health woes from the dangerous cold snap, and a Tennessee hospital breaks a heart transplant record. Bradley ...

Retatrutide, Eli Lilly's drug candidate under development, showed around a 20% placebo-corrected weight loss at a similar stage in its trial but was tested in heavier patients. Novo Nordisk's ...

Retatrutide, Eli Lilly's drug candidate under development, showed around a 20% placebo-corrected weight loss at a similar stage in its trial but was tested in heavier patients. Novo Nordisk's ...

Not to be outdone, Lilly is also working on a new “next-generation weight-loss drug” retatrutide, which targets three hormones: GLP-1, GIPR and glucagon. However, analysts have said that premilinary ...

The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct effects of these drugs is the subject of intense interest. Although reductions in ...

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to crown any winners in the race for the next generation of anti-obesity ...

Retatrutide activates the GIP, GLP-1, and glucagon receptors that are involved with controlling hunger and satiety, allowing people to feel fuller after eating for longer. This helps to regulate blood ...